New drug offers hope for severe itch from skin lumps
NCT ID NCT06773403
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug upadacitinib in 5 adults with moderate-to-severe prurigo nodularis, a condition causing very itchy skin bumps. The main goal was to see if it reduces itching by at least 4 points on a scale after 12 weeks. The study was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRURIGO NODULARIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Eczema Treatment Center of New Jersey
East Windsor, New Jersey, 08520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a CBD cream soothe Eczema's relentless itch?
- Can a biologic drug quiet the relentless itch of prurigo nodularis?
- Skin disease evolution under the microscope: a 17-Year look at what drives severity
- New drug aimed at calming the itch of prurigo nodularis enters human testing
- New injection shows promise for relieving intense itching
- New shot aims to stop the maddening itch of prurigo nodularis